KIT and gastrointestinal stromal tumor: The therapeutic effect of imatinib, a tyrosine kinase inhibitor, in gastrointestinal stromal tumors (GIST) is also associated with downregulation of IDO1 expression, which, in turn, is driven by the oncogenic tyrosine-protein kinase KIT signaling.